著者
Anthony C. Keech Kazuma Oyama Peter S. Sever Minao Tang Sabina A. Murphy Atsushi Hirayama Chen Lu Leslie Tay Prakash C. Deedwania Chung-Wah Siu Armando Lira Pineda Donghoon Choi Min-Ji Charng John Amerena Wan Azman Wan Ahmad Vijay K. Chopra Terje R. Pedersen Robert P. Giugliano Marc S. Sabatine on behalf of the FOURIER Study Group
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-20-1051, (Released:2021-05-12)
参考文献数
19
被引用文献数
1

Background:There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial, which randomized stable atherosclerosis patients to receive either evolocumab or placebo.Methods and Results:Effects of adding evolocumab vs. placebo to background statin therapy on low-density lipoprotein cholesterol (LDL-C) reductions, cardiovascular outcomes, and adverse events were compared among 27,564 participants with atherosclerotic disease, according to self-reported Asian (n=2,723) vs. other (n=24,841) races followed for a median of 2.2 years in the FOURIER trial. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. At randomization, Asians had slightly lower LDL-C (median 89 [IQR 78–104] mg/dL vs. 92 [80–109] mg/dL; P<0.001) and were much less likely to be on a high-intensity statin (33.3% vs. 73.3%; P<0.001). Evolocumab lowered LDL-C more in Asians than in others (66% vs. 58%; P<0.001). The effect of evolocumab on the primary endpoint was similar in Asians (HR, 0.79; 95% CI, 0.61–1.03) and others (HR, 0.86; 95% CI, 0.79–0.93; P interaction=0.55). There was no excess of serious adverse events with evolocumab among Asians over others.Conclusions:Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others.

言及状況

外部データベース (DOI)

Twitter (7 users, 9 posts, 17 favorites)

非アジア人と同様にアジア人においても、長期間のPCSK9阻害薬エボロクマブの使用は、LDL-Cを十分に低下させることで心血管イベントのリスクを低下させ、かつ安全であった。 By 大山 宗馬 @KazumaOyama https://t.co/3rM44uVlFa #circ_j https://t.co/dbb3EThhFD
Long-term use of PCSK9 inhibitor evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in non-Asians. By Kazuma Oyama @KazumaOyama https://t.co/3rM44uVlFa #circ_j https://t.co/FgCskCQIhH
Good news for Asian pts with ASCVD: New data from #FOURIER shows adding #PCSK9 inhibitor #evolocumab to statin robustly lowers LDL-C and is as equally safe & efficacious to prevent CV events in Asians as in non-Asians. @KazumaOyama @rgiugliano https://t.co/yhXdZszbwW

収集済み URL リスト